Association of the British Pharmaceutical Industry

UK pharmaceutical R&D investment: £9.3bn in 2024. Growing at 3.3 per cent a year, against a global 6.7 per cent. An estimated £3.8bn of investment foregone since 2020. www.abpi.org.uk/publications...

abpi.org.ukGuest article from NHS England: New funding approaches to drive adoption of innovative medicines pilotThis text will show in the Social Media caption.

A new pilot will test whether tackling local affordability barriers can speed up fair, equitable access to innovative meds for COPD, kidney disease & heart failure. David Glover, NHSE, writes on @abpi.bsky.social about what it means for patients & life sciences 👇 www.abpi.org.uk/media/blogs/...

In a new blog, Marion Laverty, ABPI Head of Public Affairs Northern Ireland, talks about treating medicines as an investment, not a cost. This is in our new vision for health and growth in Northern Ireland, launched at #NICON26 www.abpi.org.uk/media/blogs/... @niconfederation.bsky.social

Meet the first ever ABPI Youth Advisory Council 👋 8 young people aged 16-19 from across the UK will be working with us over the coming year to shape how the pharmaceutical industry talks to Gen Z. Find out more: www.abpi.org.uk/media/news/2...

Today we've published our vision for Northern Ireland at #NICON26 💊💉 It shows how the government in NI can boost health and growth through clinical research, secure health data and faster access to medicines and vaccines. www.abpi.org.uk/publications... @niconfederation.bsky.social #LifeSciences

The UK attracted more pharmaceutical FDI in the first half of 2026 (£167.2m) than in all of 2025 (£88.8m). A change in direction. Not yet a change in position. www.abpi.org.uk/publications...

The ABPI’s 2026 flagship Competitiveness Report finds that the UK has begun to reverse years of decline. Sustained delivery of government commitments will now determine whether the recovery holds: www.abpi.org.uk/media/news/2...

22 Sept

At our Regulatory Science Symposium, the @mhragovuk.bsky.social talked about improvements it has made, including to approval times for new medicines, and a partnership with the US FDA that will support scientific exchange.

22 Sept

The ABPI's third Regulatory Science Symposium is underway today, exploring how the UK can lead on regulatory innovation and scientific breakthroughs. We will discuss where the UK's regulatory offer can be genuinely distinctive. @mhragovuk.bsky.social

22 Sept

A year ago, the UK was losing ground on pharmaceutical investment. Today the picture is more hopeful: £2bn of new investment committed since September 2025. But the recovery is not yet secure. Our 2026 competitiveness report benchmarks the UK against 12 markets: www.abpi.org.uk/publications...

abpi.org.ukNICE has updated how it values quality of life - the move from 3L to 5LA shift in how NICE measures treatment benefits could restrict access to some medicines, particularly those improving quality of life without extending survival. Alan Lamb explains the change from EQ-...

28 Aug

.@nicecomms.bsky.social has adopted a new methodology for valuing quality of life in medicines appraisals. The change needs careful monitoring across all therapy areas. Read more in our latest blog 👇 www.abpi.org.uk/media/blogs/...

abpi.org.ukThe Health Data Research Service: a once-in-a-generation chance to lead the worldThe UK holds one of the world's most valuable health data assets, with GP records capturing around 90% of a patient's NHS interactions over their lifetime. ABPI Director Janet Messer explains why the ...

20 Aug

The UK holds one of the richest health data assets in the world. Our new report sets out how the Health Data Research Service (HDRS) can turn that potential into a global research advantage for patients. Read the blog by ABPI's Janet Messer: www.abpi.org.uk/media/blogs/... #HealthData #LifeSciences

abpi.org.ukThe NHS Federated Data Platform, the Single Patient Record and the Health Data Research Service – what are they, and how do they relate to the UK’s pharmaceutical industry?The NHS Federated Data Platform, the Single Patient Record and the Health Data Research Service have become hot topics of discussion in recent times. This article explains what each one is, and how th...

18 Aug

'The NHS Federated Data Platform, the Single Patient Record and the Health Data Research Service – what are they, and how do they relate to the UK’s pharmaceutical industry?' We hear you ask... Well, let's explain: www.abpi.org.uk/media/blogs/...

gov.ukPatients to benefit from faster access to medicines as UK moves away from animal testing in scienceNew projects to move UK science away from animal testing

13 Aug

.@chrismcdonaldmp.bsky.social has announced plans for a new £20 million pre-clinical translational models hub in Cambridge, a concept @abpi.bsky.social and our members have long championed. www.gov.uk/government/n...

abpi.org.ukNew pre-clinical translational models hub to accelerate development of human-relevant models for medicines discoveryJoanna Jenkinson discusses plans for a new £20 million pre-clinical translational models hub in Cambridge, a concept the ABPI and its members have long championed. Led by the Medical Research Council,...

13 Aug

In this piece, we discuss the work the ABPI and our members have done to get us to this point, and how the Hub can help bring together industry and academic researchers across the UK to develop better, more human-relevant pre-clinical models. www.abpi.org.uk/media/blogs/...

24 July

Find out what’s needed to give people faster and fairer access to the latest treatments, so they can live longer, healthier lives. Visit: www.abpi.org.uk/reputation/b...

20 July

On the resignation of Lord Vallance, Richard Torbett said: “Lord Vallance has been a tremendous Science Minister and a genuine champion for the UK's life sciences sector. He has been instrumental in beginning to turn around international sentiment towards the UK as a life sciences destination."

www.abpi.org.uk/media/news/2...

20 July

abpi.org.ukABPI comment on resignation of Lord VallanceOn the resignation of Lord Vallance as Science Minister, Richard Torbett, Chief Executive of the ABPI, said: “Patrick Vallance has been a tremendous Science Minister and a genuine champion for the U...

gov.ukUK Switzerland FTA Top Benefits11 top benefits of the largest services trade deal concluded by the UK

13 July

This landmark agreement between the UK and Switzerland, two nations with a long history of collaboration in life sciences, is built on a shared understanding of what is needed to support innovation and bring new medicines to patients. www.gov.uk/government/n...

abpi.org.ukDisclosure UK 2025: the 11th year of Disclosure UK data, with industry transparency continuing to growDr Amit Aggarwal, ABPI Executive Director of Medical Affairs and Strategic Partnerships, and Alex Fell, PMCPA Chief Executive, discuss the latest data published on Disclosure UK, the industry database...

30 June

Today we have published the latest Disclosure UK data. Disclosure UK records payments & benefits in kind made by pharmaceutical companies to healthcare professionals, healthcare organisations and NHS organisations. Read our latest blog post here: www.abpi.org.uk/media/blogs/...

19 June

Today we've gone #Red4Research! 🧬 🔬 🩺 Through industry clinical research, scientific breakthroughs can become life-changing medicines for patients. Thank you to all the scientists, clinicians, & patients who make health and care research happen. 🔴 @nihr.bsky.social @hralatest.bsky.social

gov.ukProposed 2026 changes to the statutory scheme for branded medicines pricingProposed changes to the headline payment percentage and consultation procedure of the statutory scheme to control the cost of branded health service medicines.

10 June

Following a consultation, the Department of Health and Social Care will implement its proposals to reduce the statutory scheme's headline payment percentage for 2026 and beyond to 16.5%, maintaining broad commercial equivalence with the Voluntary Scheme. www.gov.uk/government/c...

10 June

The department also plans to launch an alternative approach to consulting on future adjustments, using direct engagement through workshops with industry and patient groups. Importantly, this still includes an option to submit written evidence, ensuring anyone has the opportunity to have their say.

4 June

Pleased to be supporting the Newcomer of the Year award at this years @absw.bsky.social awards! Good luck to all finalists!

ABSW@absw.bsky.social

📣 #ABSWawards Finalists announced! 🔗 zurl.co/ghOYq Of note this year were the range of pieces focused on the cuts to scientific research funding in the USA. UK and Irish journalists investigated the impact on individuals, institutions and communities both in the USA and internationally.

youtube.comThe clinical trial processYouTube video by Association of the British Pharmaceutical Industry

20 May

On International Clinical Trials Day, we're highlighting the importance of clinical trials, without which we would have no new medicines or vaccines. Dr Janet Valentine explains below. #ICTD @nihr.bsky.social @hralatest.bsky.social @mhragovuk.bsky.social www.youtube.com/watch?v=PaqV...

abpi.org.ukA Design for Life Sciences - Delivering Health, Growth, and Investment - Wales ABPI manifesto 2025This plan for Wales sets out the ABPI’s vision for improving health outcomes, supporting the health system, and stimulating inward investment and economic growth.

19 May

Delighted to welcome a new @plaidcymru.bsky.social government under @rhunapiorwerth.bsky.social's leadership. We will continue our work to support equitable access to innovation, drive health & economic ambitions to deliver better health outcomes for people in Wales. www.abpi.org.uk/publications...

Plaid Cymru@plaidcymru.bsky.social

Prif Weinidog Cymru - Rhun ap Iorwerth. Rhun ap Iorwerth - your new First Minister of Wales. 🏴󠁧󠁢󠁷󠁬󠁳󠁿

abpi.org.ukAre NHS patients keeping up with European neighbours on access to new medicines?NHS patients in England rank 7th in Europe for access to newly approved medicines, according to the latest EFPIA W.A.I.T. Indicator report — but significant gaps remain, particularly for cancer and ra...

19 May

📋 New blog from ABPI's Sophie Caseby unpacking the latest EFPIA W.A.I.T. Indicator report. England ranks 7th in Europe for access to newly approved medicines overall — but 14th for cancer treatments. What's driving the gap, and what needs to change? 👇 www.abpi.org.uk/media/blogs/...

8 May

Medicines supply issues are relatively rare, but when they happen, they can have a serious impact on patients. Our new report sets out how to improve the supply chain to anticipate risks and respond quickly when disruption occurs. Read more: www.abpi.org.uk/publications...

6 May

Decentralised or hybrid clinical trials can bring research closer to home - boosting access & inclusion. A new @acmedsci.bsky.social report, supported by us + @nihr.bsky.social shows how to encourage more of these trials: choice, trust & clearer guidance. acmedsci.ac.uk/file-downloa...

29 Apr

We are celebrating World Immunization Week🎉 Vaccines have safely protected people, families, and communities for generations and as part of our free learning resources for schools you can find out more about the importance of vaccinations with Ellie. www.abpischools.org.uk/topics/ellie...

The panel discussed how co-creation between industry, academia, government and the NHS is essential to remove barriers and expand access to research. #ABPIconf26

Next up is our clinical trials panel! Improvements in regulatory performance, alongside the UK’s unique health data assets, are strengthening the environment for commercial and non commercial clinical trials. For industry, the priorities are clear: predictability, accuracy and speed. #ABPIconf26

The ABPI Exam offers qualifications for industry personnel to have the understanding they need to promote medicines ethically. Each year, we recognise the candidate who has achieved the highest grade. Congratulations to Pedro Figueiredo Aparicio from Johnson & Johnson Innovative Medicine UK! 🎉👏🏆

Panellists pointed to the value of bringing together industry, government, academia and the health system to unlock the UK’s full potential. #ABPIconf26

A strong start to today’s growth panel on where the UK can win globally. The discussion pointed to a clear opportunity for the UK at the intersection of life sciences and AI, with healthcare seen as one of the most promising settings for innovation to flourish. #ABPIconf26

Opening, our Chief Executive said the UK is starting to choose growth, innovation and faster patient access to medicines. We've long known of problems in the UK - 102 medicines launched in the US have not launched in European markets, vs 15 the other way round.

Our annual conference is underway! We’re looking forward to a full agenda discussing how best to position the UK as a leading place to research, develop and use innovative medicines. #ABPIconf26

British Society for Immunology

22 Apr

Vaccination is one of the most effective ways to protect people’s health, preventing illness and reducing pressure on the NHS. Find out more about the value of vaccination: www.abpi.org.uk/value-and-ac... #Vaccination #EIW2026 #WIW2026

Association of the British Pharmaceutical Industry reposted

@britsocimm.bsky.social

25 Mar

Vaccine Engagement Day 2026 has arrived! 🎉 Let’s come together to #CelebrateVaccines by sharing information and enhancing public awareness about vaccines!🌟 Discover how you can participate: vist.ly/4v2vi

23 Mar

The use of NHS data has the potential to transform commercial clinical trials in the UK by making recruitment faster, more efficient, and participation more inclusive. Read our latest report: “Globally competitive UK-wide data-enabled clinical trials: the time is now www.abpi.org.uk/publications...

abpi.org.ukInnovation with integrity: Why NHS-industry partnerships matter, and how conflicts of interest are managedDr Amit Aggarwal discusses the importance of NHS-industry relationships, and the safeguards in place to ensure they always put patients and the NHS first.

19 Mar

NHS–industry partnerships are essential for high-quality healthcare. But they can mean conflicts of interest. Read our blog that explains the safeguards on this - including our strict Code of Practice & independent regulation. 📖 Read more: www.abpi.org.uk/media/blogs/...

hira-ni.comImproving Health, Supporting Economic Growth | (HIRANI) Health Innovation Research Alliance Northern IrelandBy Marion Laverty, Head of Public Affairs, Northern Ireland, Association of the British Pharmaceutical Industry (ABPI)

12 Mar

Strengthening Northern Ireland’s health and economy through life sciences leadership. 🧬🔬💊💉 Read our colleague Marion Laverty's piece on the ABPI's work in Northern Ireland for @hiranihealth.bsky.social hira-ni.com/improving-he...

youtube.comWhat is Disclosure UKYouTube video by Association of the British Pharmaceutical Industry

11 Mar

🚨New video: Understanding Disclosure UK Learn how the pharmaceutical industry’s transparency database works, and how it forms part of wider frameworks for managing conflicts of interest. Watch below ⬇️ www.youtube.com/watch?v=pT5e...

11 Mar

Partnerships between the NHS and the pharmaceutical industry play an important role in improving patient outcomes. Dr Amit Aggarwal sets out why these relationships matter and the safeguards to ensure transparency and manage conflicts of interest. www.abpi.org.uk/media/blogs/...

6 Mar

NEW: Our Medical Director Dr Amit Aggarwal's comment on NHS-industry partnerships and the safeguards in place to manage conflicts of interest. Companies may also benefit from partnerships, but the priority has to be to put the NHS & patients first. www.abpi.org.uk/media/blogs/...

5 Mar

Our colleague Brian Duggan spoke at the APPG for Black Health event on increasing diversity in clinical trials @paulettehamiltonmp.bsky.social Lack of diversity in clinical trials is a huge issue that has real consequences for health. Read his reflections: abpi.org.uk/media/blogs/...

youtube.comInshiya and Nina - Medical Affairs GraduatesYouTube video by Association of the British Pharmaceutical Industry

2 Mar

This @careersweek.bsky.social we're showcasing the diverse range of roles within the pharmaceutical industry. If you’re exploring your next step or curious about what a career in the industry can look like visit our job cases studies: www.abpi.org.uk/careers/job-... www.youtube.com/watch?v=uaoE...

27 Feb

Equity in rare diseases means equal access to diagnosis, treatment, health and social care, and the opportunity to fully participate in society. Read the @geneticallianceuk.bsky.social report on this: geneticalliance.org.uk/wp-content/u... #RareDiseaseDay #RareEquity

abpi.org.ukAlan and Ataxia: Explaining the lived experience of a rare diseaseAlan Thomas from Wales is a patient advocate for rare diseases and Ataxia in particular. Known as ‘the rare disease warrior’; he founded the charity Ataxia and Me, which now has a global following. He...

27 Feb

For #RareDiseaseDay we’re sharing Alan’s amazing journey with ataxia - he founded Ataxia and Me to raise awareness and connect people around the world. 🌍 Thanks to @geneticallianceuk.bsky.social for championing every voice in the rare disease community. 💪 abpi.org.uk/media/blogs/...